摘要
目的观察益气化痰祛瘀方对慢性阻塞性肺病(COPD)急性加重期病人血清同型半胱氨酸(Hcy)、组织纤溶酶原激活物(t-PA)、纤溶酶原激活物抑制物-1(PAI-1)水平的影响。方法将安徽中医药大学第一附属医院呼吸内科2017年6月至2019年9月收治住院的60例COPD急性加重期痰瘀阻肺型病人,按照受试者入选的先后顺序查阅随机对照表分为治疗组、对照组各30例,对照组给予抗感染、化痰、解痉平喘等常规西医治疗,治疗组在此基础上服用中药益气化痰祛瘀方,治疗14 d后观察两组症候积分比较、治疗前后Hcy、t-PA、PAI-1水平。结果治疗后两组舌质积分改善不明显(P>0.05),其他症候积分较治疗前明显改善(P<0.01),其中咳嗽、咳痰较对照组比较无明显差异(P>0.05),喘息、纳呆、腹胀、口粘苔腻、面色或唇甲青紫方面优于对照组(P<0.05或P<0.01)。两组治疗后Hcy、PAI-1水平较治疗前明显下降[(15.59±2.79)比(13.34±2.18)μmol/L、(61.13±8.30)比(45.03±8.68)pg/mL,P<0.05或P<0.01],t-PA水平较治疗前明显升高(0.69±0.12)ng/mL,P<0.01,且对照组优于治疗组(P<0.05或P<0.01)。结论益气化痰祛瘀方可能通过降低血Hcy水平减轻内皮细胞损伤,改善纤溶失衡状态,从而有效缓解COPD痰瘀阻肺证病人临床症候,延缓疾病进展。
Objective To observe the effect of Yiqi Huatan Quyu Recipe on the levels of Hcy,t-PA and PAI-1 in patients withacute exacerbation of chronic obstructive pulmonary disease(AECOPD).MethodsFrom June 2017 to September 2019,60 AECO-PD patients from the respiratory department of the First Affiliated Hospital of Anhui University of Traditional Chinese Medicinewere randomly divided into the treatment group and the control group with 30 cases in each group,according to the sequence ofsubjects selected and the random control table.The control group was treated with routine western medicine such as anti-infection,phlegm-resolving,spasmolysis and asthma-relieving.On this basis,the treatment group took Yiqi Huatan Quyu Recipe.After 14 daysof treatment,the scores of symptoms,the levels of Hcy,t-PA and PAI-1 before and after treatment were observed.ResultsAftertreatment,there was no significant improvement in tongue integral between the two groups(P>0.05).The scores of other symptomswere significantly improved compared with those before treatment(P<0.01).There was no significant difference in cough and spu-tum between the two groups(P>0.05).The symptoms of asthma,dullness,abdominal distension,greasy mouth,bluish complexionor purple lip nails of the control group were better than those of the control group(P<0.05 or P<0.01).After treatment,the levelsof Hcy and PAI-1 in the two groups decreased significantly(15.59±2.79)vs.(13.34±2.18)μmol/L,(61.13±8.30)vs.(45.03±8.68)pg/mL,P<0.05 or P<0.01)and t-PA increased significantly(0.69±0.12 ng/mL,P<0.01),and the control group was better thanthe treatment group(P<0.05 or P<0.01).Conclusion Yiqi Huatan QuyuPrescription may reduce endothelial cell injury and im-prove fibrinolysis imbalance by reducing blood Hcy level,so as to effectively alleviate clinical symptoms of chronic obstructive pul-monary disease with phlegm and blood stasis obstruction and improve clinical efficacy.
作者
徐升
张念志
徐经世
XU Sheng;ZHANG Nianzhi;XU Jingshi(Department of Respiratory,the First Affiliated Hospital of Anhui University of Traditional Chinese Medicine,Hefei,Anhui 230031,China)
出处
《安徽医药》
CAS
2020年第7期1440-1443,共4页
Anhui Medical and Pharmaceutical Journal
基金
国家中医药管理局“十二五”中医药重点学科建设项目(国中医药办人教发〔2012〕32号)
国家中医药管理局第二届国医大师传承工作室建设项目(国中医药办人教发〔2015〕24号)。
关键词
肺疾病
慢性阻塞性/中药疗法
痰郁
益气祛瘀
半胱氨酸
组织型纤溶酶原激活物
纤溶酶原激活物抑制物1
Pulmonary disease,chronic obstructive/zhong yao liao fa
Phlegm depression
Reinforcing qi removing stasis
Cysteine
Tissue plasminogen activator
Plasminogen activator inhibitor 1
